COMMUNIQUÉS West-GlobeNewswire

Dogecoin Cash, Inc. Announces Completion of Unit Distribution Processing and DTC Participant Allocation
29/01/2026
MESQUITE, NV, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Mesquite, Nevada - January 29, 2026 - Dogecoin Cash, Inc. (OTC: DOGP) (the "Company") today announced that Colonial Stock Transfer Company, Inc. ("Colonial"), the Company' [...]
Study Results of Novel TYK2 Inhibitor Soficitinib in Patients with AD Published by JAMA Dermatology
29/01/2026
BEIJING, Jan. 29, 2026 (GLOBE NEWSWIRE) -- JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis (AD). [...]
Aicuris Announces Pritelivir Phase 3 HSV Data to Be Presented as Late-Breaking Oral Presentation at Tandem
29/01/2026
Wuppertal, Germany, January 29, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced that the company will be presenting the results of pritelivir from their pivotal Phase 3 trial (PRIOH-1, NCT03073967 ) [...]
ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
29/01/2026
MELBOURNE, Australia, Jan. 29, 2026 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory [...]
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
29/01/2026
REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has [...]
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
29/01/2026
REYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Interim Results for the six months ended 31 October 2025
29/01/2026
OXFORD, United Kingdom, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody ® and Moditope ® active immunotherapies to treat cancer, today announces a business update and [...]
Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026
29/01/2026
2025: strong sales and EPS growth. Continued profitable growth expected in 2026 Paris, January 29, 2026 Q4 sales growth of 13.3% at CER 1 and business earnings per share (EPS) 2 of €1.53 Pharma launches increased sales [...]
Communiqué de presse : 2025 : année de forte croissance du chiffre d’affaires et du BNPA. Poursuite d’une croissance rentable attendue en 2026
29/01/2026
2025 : année de forte croissance du chiffre d’affaires et du BNPA. Poursuite d’une croissance rentable attendue en 2026. Paris, le 29 janvier 2026 Ventes du T4 en progression de 13,3 % à TCC 1 et BNPA 2 des activités de [...]
OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab
29/01/2026
OSE Immunotherapeutics sélectionne la pouchite chronique et l’hidradénite suppurée comme nouvelles indications clés pour Lusvertikimab Développement basé sur un fort rationnel biologique de l’IL-7R La pouchite chronique [...]
Ipsen nomme Peter Guenter au sein de son Conseil d’Administration
29/01/2026
PARIS, FRANCE, 29 janvier 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd'hui la cooptation de Peter Guenter au sein de son Conseil d'Administration en tant qu'Administrateur, à compter du 28 janvier 2026, [...]
Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors
29/01/2026
Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGene IFLI contributed up to $9 million to Enterome’s private funding round in 2025 Enterome has announced a series of encouraging clinical [...]
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
29/01/2026
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationale Chronic Pouchitis offers a capital-efficient [...]
Ipsen nominates Peter Guenter to its Board of Directors
29/01/2026
PARIS, FRANCE, 29 January 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Peter Guenter to its Board as a Director, effective January 28, 2026, further to the vacancy of Mr. Henri Beaufour’s [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
29/01/2026
Group sales grew by 7% 1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions. Sales in the fourth quarter increased by 8%, reflecting the positive momentum. [...]
TomorrowsRx Telehealth Service Outlines Prescription Access for Compounded Semaglutide and Advanced Tirzepatide Formulations
29/01/2026
An informational overview examining what consumers often consider when researching telehealth-based prescription weight management treatment access through physician-supervised platforms SAN MARCOS, CA, Jan. 28, 2026 ( [...]
Ryoncil® Net Revenues Increase for the Quarter to US$30M
29/01/2026
Activity Report for Quarter Ended December 31, 2025 (Appendix 4C) NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory [...]
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
29/01/2026
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) [...]
L’Association canadienne pour l’équité en santé des femmes annonce une séance Conversations vitales sur les menstruations et la santé hormonale tout au long de la vie, présentée par Vichy Laboratoires
28/01/2026
Cycle menstruel, ménopause et plus encore – des expertes présenteront l’influence des hormones sur la santé des femmes à toutes les étapes de leur vie TORONTO, 28 janv. 2026 (GLOBE NEWSWIRE) -- L’Association canadienne [...]

Pages